Treatment for IgG and IgA paraproteinaemic neuropathy

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 3, 2015, Pages

  Stork, Abraham C J ^a   Lunn, Michael P T ^b   Nobile Orazio, Eduardo ^c   Notermans, Nicolette C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTION POTENTIAL AMPLITUDE; HUMAN; IMMUNOGLOBULIN A PARAPROTEINEMIC NEUROPATHY; IMMUNOGLOBULIN G PARAPROTEINEMIC NEUROPATHY; IMMUNOPATHOLOGY; MOTOR NERVE CONDUCTION; MUSCLE ACTION POTENTIAL; MUSCLE STRENGTH; NEUROPATHY DISABILITY SCORE; PERIPHERAL NEUROPATHY; PLASMA EXCHANGE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; VIBRATION SENSE; WEAKNESS; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; PERIPHERAL NERVOUS SYSTEM DISEASES; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; PERIPHERAL NERVOUS SYSTEM DISEASES; PLASMA EXCHANGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942766320     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005376.pub3     Document Type: Review

References (56)

1. Dyck P, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. New England Journal of Medicine 1991;325(21):1482-6. [PUBMED: 1658648]
2. Léger JM, Younes-Chennoufi AB, Chassande B, Davila G, Bouche P, Baumann N, et al. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. Journal of Neurology, Neurosurgery & Psychiatry 1994;57 Suppl:46-9.
3. Notermans NC, Lokhorst HM, Franssen H, Van der Graaf Y, Teunissen LL, Jennekens FG, et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology 1996;47(5):1227-33.
4. Notermans NC, Vermeulen M, Van Doorn PA, Van den Berg LH, Teunissen LL, Wokke JH. Pulsed high-dose dexamethasone treatment of polyneuropathy associated with monoclonal gammopathy. Journal of Neurology 1997;244(7):462-3.
5. Sghirlanzoni A, Solari A, Ciano C, Mariotti C, Fallica E, Pareyson D. Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurological Sciences 2000;21(1):31-7.
6. Bailey RO, Ritaccio AL, Bishop MB, Wu AY. Benign monoclonal IgAK gammopathy associated with polyneuropathy and dysautonomia. Acta Neurologica Scandinavica 1986;73(6):574-80.
7. Bleasel AF, Hawke SH, Pollard JD, McLeod JG. IgG monoclonal paraproteinaemia and peripheral neuropathy. Journal of Neurology, Neurosurgery & Psychiatry 1993;56(1):52-7.
8. Bromberg MB, Feldman EL, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients with and without an associated monoclonal gammopathy. Neurology 1992;42(6):1157-63.
9. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology 1991;41(5):617-8.
10. Di Troia A, Carpo M, Meucci N, Pellegrino C, Allaria S, Gemignani F, et al. Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. Journal of the Neurological Sciences 1999;164(1):64-71.
11. Dyck PJ, Boes CJ, Mulder D, Millikan C, Windebank AJ, Dyck PJ, et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. Journal of the Peripheral Nervous System 2005;10(2):158-73.
12. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Edition. Journal of the Peripheral Nervous System 2010;15(3):185-95.
13. Eurelings M, Notermans NC, Van de Donk NW, Lokhorst HM. Risk factors for haematological malignancy in polyneuropathy associated with monoclonal gammopathy. Muscle & Nerve 2001;24(10):1295-302.
14. Eurelings M, Notermans NC, Wokke JH, Bosboom WM, Van den Berg LH. Sural nerve T cells in demyelinating polyneuropathy associated with monoclonal gammopathy. Acta Neuropathologica 2002;103(2):107-14.
15. Eurelings M, Van den Berg LH, Wokke JHJ, Franssen H, Vrancken AFJ, Notermans NC. Increase of sural nerve T cells in progressive axonal polyneuropathy and monoclonal gammopathy. Neurology 2003;61(5):707-9.
16. Fazio R, Nemni R, Quattrini A, Lorenzetti I, Canal N. IgG monoclonal proteins from patients with axonal peripheral neuropathies bind to different epitopes of the 68kDa neurofilament protein. Journal of Neuroimmunology 1992;36(2-3):97-104.
17. Gorson KC, Ropper AH. Axonal neuropathy associated with monoclonal gammopathy of undetermined significance. Journal of Neurology, Neurosurgery & Psychiatry 1997;63(2):163-8.
18. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48(2):321-8.
19. Gorson KC, Ropper AH, Weinberg DH, Weinstein R. Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Archives of Neurology 2002;59(5):766-72.
20. Gosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathies of undetermined significance. Annals of Neurology 1991;30(1):54-61.
21. Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEpro. 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.
22. Hermosilla E, Lagueny A, Vital C, Vital A, Ferrer X, Steck A, et al. Peripheral neuropathy associated with monoclonal IgG of undetermined significance: clinical, electrophysiologic, pathologic and therapeutic study of 14 cases. Journal of the Peripheral Nervous System 1996;1(2):139-48.
23. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) March 2011. Available from www.cochrane-handbook.org.
24. Kelly JJ, Kyle RA, O'Brien P, Dyck PJ. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981;31(11):1480-3.
25. Kiprov DD, Golden P, Rohe R, Smith S, Hofmann J, Hunnicutt J. Adverse reactions associated with mobile therapeutic apheresis: analysis of 17, 940 procedures. Journal of Clinical Apheresis 2001;16(3):130-3.
26. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle & Nerve 1991;14(11):1103-9.
27. Kyle R. Plasma cell dyscrasia: definition and diagnostic evaluation. In: Kelly J, Kyle R, Latov N editor(s). Polyneuropathies associated with plasma cell dyscrasias. Boston: Martinus Nijhoff Publishing, 1987:1-28.
28. Kyle RA. Diagnostic criteria of multiple myeloma. Hematology/Oncology Clinics of North America 1992;6(2):347-58.
29. Kyle RA. 'Benign' monoclonal gammopathy-after 20 to 35 years of follow up. Mayo Clinic Proceedings 1993;68(1):26-36.
30. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD002827.pub3]
31. Magy L, Chassande B, Maisonobe T, Bouche P, Vallat J, Léger J. Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiological study of 15 cases. European Journal of Neurology 2003;10(6):677-85.
32. Mehndiratta MM, Sen K, Tatke M, Bajaj BK. IgA monoclonal gammopathy of undetermined significance with peripheral neuropathy. Journal of Neurological Sciences 2004;221(1-2):99-104.
33. Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA, for the European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Psychometric evaluation of a new sensory scale in immune-mediated neuropathies. Neurology 2000;54(4):943-9.
34. Merkies I, Schmitz P, van der Meche F, Samijn J, van Doorn P, for the Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Psychometric evaluation of an overall disability scale in immune-mediated neuropathies. Journal of Neurology, Neurosurgery & Psychiatry 2003;74(1):99-104.
35. Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA. Comparison between impairment and disability scales in immune-mediated polyneuropathies. Muscle & Nerve 2003;28(1):93-100.
36. Merkies IS, Lauria G. 131st ENMC international workshop: selection of outcome measures for peripheral neuropathy clinical trials 10-12 December 2004, Narden, The Netherlands. Neuromuscular Disorders 2006;16(2):149-56.
37. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology 2003;121(5):749-57.
38. Nobile-Orazio E, Barbieri S, Baldini L, Marmiroli P, Carpo M, Premoselli S, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenic studies. Acta Neurologica Scandinavica 1992;85(6):383-90.
39. Nobile-Orazio E, Casellato C, Di Troia A. Neuropathies associated with IgG and IgA monoclonal gammopathy. Revue Neurologique 2002;158(10 Pt 1):979-87.
40. Notermans NC, Wokke JHJ, Lokhorst HM, Franssen H, van der Graaf Y, Jennekens FG. Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities. Brain 1994;117(Pt 6):1385-93.
41. Notermans NC, Wokke JHJ, van den Berg L, van der Graaf Y, Franssen H, Teunissen LL, et al. Chronic idiopathic axonal polyneuropathy. Comparison of patients with and without monoclonal gammopathy. Brain 1996;119(Pt 2):421-7.
42. Notermans NC, Franssen H, Eurelings M, Van der Graaf Y, Wokke JH. Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy. Muscle & Nerve 2000;23(1):73-9.
43. Ponsford S, Willison H, Veitch J, Morris R, Thomas PK. Long term clinical and neurophysiological follow up of patients with peripheral neuropathy associated with benign monoclonal gammopathy. Muscle & Nerve 2000;23(2):150-2.
44. Ritzmann S, Loukas D, Sakai H, Daniels JC, Levin WC. Idiopathic (asymptomatic) monoclonal gammopathies. Archives of Internal Medicine 1975;135(1):95-106.
45. Saleun JP, Vicariot M, Deroff P, Morin J. Monoclonal gammopathies in the adult population of Finistere, France. Journal of Clinical Pathology 1982;35(1):63-8.
46. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle & Nerve 2001;24(3):311-24.
47. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology 1993;43(11):2202-9.
48. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long term follow up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995;118(Pt 2):359-68.
49. Stubbs EB, Lawlor MW, Richards MP, Siddiqui K, Fisher MA, Bhoopalam N, et al. Anti-neurofilament antibodies in neuropathy with monoclonal gammopathy of undetermined significance produce experimental motor nerve conduction block. Acta Neuropathologica 2003;105(2):109-16.
50. Vallat J, Tabaraud F, Sindou P, Preux M, Van den Berghe A, Steck A. Myelin widenings and MGUS-IgA: an immunoelectronmicroscopic study. Annals of Neurology 2000;47(6):808-11.
51. Vital A, Lagueny A, Julien J, Farrer X, Barat M, Hermosilla E, et al. Chronic inflammatory demyelinating polyneuropathy associated with dysglobulinaemia: a peripheral nerve biopsy study in 18 cases. Acta Neuropathologica 2000;100(1):63-8.
52. Vrethem M, Cruz M, Wen-Xin H, Malm C, Holmgren H, Ernerudh J. Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. Journal of the Neurological Sciences 1993;114(2):193-9.
53. Vrethem M, Reiser N, Lauermann C, Svanborg E. Polyneuropathy associated with IgM vs IgG monoclonal gammopathy: comparison between clinical and electrophysiological findings. Acta Neurologica Scandinavica 2010;122(1):52-57.
54. Yeung KB, Thomas PK, King RH, Waddy H, Will RG, Hughes RA, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. Journal of Neurology 1991;238(7):383-91.
55. Allen D, Lunn MPT, Niermeijer J, Nobile-Orazio E. Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005376]
56. Allen D, Lunn MPT, Niermeijer J, Nobile-Orazio E. Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD005376.pub2]